ProCE Banner Activity

Looking Toward the Future: Investigational PBC Pruritus Agents

Clinical Thought

Read my insights on exciting investigational pruritus agents on the horizon for treating primary biliary cholangitis (PBC)–related pruritus, including ileal bile acid transporter inhibitors, peroxisome proliferator-activated receptor agonists, and kappa opioid receptor agonists.

Released: May 24, 2024

Expiration: May 23, 2025

Share

Faculty

Marlyn J Mayo

Marlyn J Mayo, MD

Professor of Internal Medicine
Division of Digestive & Liver Diseases
UT Southwestern Medical Center
Dallas, Texas

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

This educational activity is supported by an educational grant from GlaxoSmithKline.

GlaxoSmithKline

Disclosure

Primary Author

Marlyn J Mayo, MD

Professor of Internal Medicine
Division of Digestive & Liver Diseases
UT Southwestern Medical Center
Dallas, Texas

Marlyn J. Mayo, MD: consultant/advisor/speaker: CymaBay, GlaxoSmithKline, Intra-Sana, Ipsen, Mallinckrodt; researcher: CymaBay, Genfit, GlaxoSmithKline, Intercept, Ipsen, Mirum.